Mark Connor
Affiliations: | University of Sydney, Camperdown, New South Wales, Australia |
Area:
Trigeminal sensory neurons, opioid receptors, ion channels, cannabinoidsGoogle:
"Mark Connor"Mean distance: 14.67 (cluster 11) | S | N | B | C | P |
Parents
Sign in to add mentor| Charles Chavkin | grad student | 1988-1992 | University of Washington | |
| (Supervisor) | ||||
| Graeme Henderson | post-doc | 1993-1996 | University of Bristol | |
| MacDonald J. Christie | post-doc | 1996-2001 | University of Sydney | |
Children
Sign in to add trainee| Stephanie L. Borgland | grad student | 1999-2002 | University of Sydney |
| Louise Roberts | grad student | 2001-2004 | University of Sydney |
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Manandhar P, Connor M, Santiago M. (2022) Tapentadol shows lower intrinsic efficacy at µ receptor than morphine and oxycodone. Pharmacology Research & Perspectives. 10: e00921 |
| Manandhar P, Murnion BP, Grimsey NL, et al. (2021) Do gabapentin or pregabalin directly modulate the µ receptor? Peerj. 9: e11175 |
| Heblinski M, Santiago M, Fletcher C, et al. (2020) Terpenoids Commonly Found in Do Not Modulate the Actions of Phytocannabinoids or Endocannabinoids on TRPA1 and TRPV1 Channels. Cannabis and Cannabinoid Research. 5: 305-317 |
| Gillis A, Gondin AB, Kliewer A, et al. (2020) Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Science Signaling. 13 |
| Sachdev S, Banister SD, Santiago M, et al. (2020) Differential activation of G protein-mediated signaling by synthetic cannabinoid receptor agonists. Pharmacology Research & Perspectives. 8: e00566 |
| Sachdev S, Boyd R, Grimsey NL, et al. (2019) Brodifacoum does not modulate human cannabinoid receptor-mediated hyperpolarization of AtT20 cells or inhibition of adenylyl cyclase in HEK 293 cells. Peerj. 7: e7733 |
| Sachdev S, Vemuri K, Banister SD, et al. (2019) In vitro determination of the CB1 efficacy of illicit synthetic cannabinoids. British Journal of Pharmacology |
| Udoh M, Santiago M, Devenish S, et al. (2019) Cannabichromene is a cannabinoid CB2 receptor agonist. British Journal of Pharmacology |
| Moir M, Lane S, Lai F, et al. (2019) Strategies to develop selective CB receptor agonists from indole carboxamide synthetic cannabinoids. European Journal of Medicinal Chemistry. 180: 291-309 |
| Kevin RC, Anderson L, McGregor IS, et al. (2019) CUMYL-4CN-BINACA Is an Efficacious and Potent Pro-Convulsant Synthetic Cannabinoid Receptor Agonist. Frontiers in Pharmacology. 10: 595 |